Posttransplant cyclophosphamide for graft-vs-host disease prophylaxis
Target Population
Patients undergoing first allogeneic hematopoietic cell transplant
Care Setting
MD Anderson Cancer Center
Key Highlights
MRDs may have a higher relapse risk compared to MUDs and MMUDs.
Posttransplant cyclophosphamide narrows the toxic effects gap between donor types.
Donor age has minimal influence on survival and relapse in the posttransplant cyclophosphamide era.
Study compares clinical outcomes between MRD and MMUD transplants.
Primary outcomes include disease-free survival (DFS) and overall survival (OS).
Guideline-Based Recommendations
Diagnosis
Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome, and myeloproliferative neoplasm are the target conditions for transplant.
Management
Posttransplant cyclophosphamide is routinely administered for GVHD prophylaxis.
Monitoring & Follow-up
Monitor for relapse, nonrelapse mortality (NRM), and graft-vs-host disease (GVHD) outcomes.
Risks
Relapse of underlying malignant tumors remains a significant risk post-transplant.
Patient & Prescribing Data
Patients with AML, ALL, or myelodysplastic syndrome/myeloproliferative neoplasm undergoing first allogeneic transplant.
MMUD grafts may exhibit a stronger graft-vs-leukemia effect than MRDs.
Clinical Best Practices
Utilize IPTW with overlap weights to balance baseline characteristics.
Apply bootstrapped resampling for stability and robustness of estimates.
Consider donor type as a significant covariate in survival analyses.
by Rohtesh S. Mehta, Yosra M. Aljawai, Partow Kebriaei, Warren Fingrut, Portia Smallbone, Betul Oran, Amanda Olson, Uday Popat, Richard E. Champlin, Elizabeth J. Shpall
